Du är här

2014-05-06

Novavax, Inc.: Novavax Appoints Sven Andreasson as Senior Vice President, Corporate Development

GAITHERSBURG, Md., May 6, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc.
(Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the
discovery, development and commercialization of recombinant nanoparticle
vaccines and adjuvants, today announced the appointment of Sven Andréasson to
the position of Senior Vice President, Corporate Development, effective June
2, 2014. Mr. Andréasson will be responsible for identifying, prioritizing and
evaluating new strategic opportunities that leverage the company's core
strengths and growth initiatives.

Mr. Andréasson brings to Novavax a long history of experience in
biopharmaceutical operations, executive management and strategic development
from his many years in the industry. From 2012 to 2013 he served as the Chief
Executive Officer of Isconova AB in Uppsala, Sweden, a leading international
vaccine adjuvant company acquired by Novavax in 2013, currently operating as
Novavax AB. Prior to his role at Isconova AB, Mr. Andréasson served as the
Chief Executive Officer of Beta-Cell NV in Brussels, Belgium from 2008 to
2012 and as Chief Executive Officer of Active Biotech AB in Lund, Sweden from
1999 to 2008. Mr. Andréasson spent a number of years in roles inside
Pharmacia Corporation including: President of Pharmacia SA, France, President
of KabiPharmacia International and President of Pharmacia Arzneimittel GmbH,
Germany.

"My first serious interactions with Sven occurred during our negotiations to
acquire Isconova AB. I was immediately impressed with him as a pragmatic and
thoughtful business professional. It became readily apparent to me that
Novavax would benefit from his extensive vaccine and pharmaceutical industry
experience and insight," said Stan Erck, President and CEO of Novavax. "I am
very excited to have someone with Sven's experience help me and the entire
management team to evaluate organic and non-organic opportunities to build
this business and increase shareholder value."

Mr. Andréasson stated, "Novavax has an impressive pipeline and a remarkably
talented and experienced team of professionals. Novavax' successful clinical
trial data over recent months underscore its potential to develop into a
major vaccine player. With today's strong platform as a base, we will
systematically evaluate promising new growth possibilities. I look forward to
joining the team of Novavax."

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biopharmaceutical company
creating novel vaccines and vaccine adjuvants to address a broad range of
infectious diseases worldwide. Using innovative proprietary recombinant
nanoparticle vaccine technology, the company produces vaccine candidates to
efficiently and effectively respond to both known and newly emergent
diseases. Additional information about Novavax is available on the company's
website, novavax.com.

Forward-Looking Statements

Statements herein relating to the future of Novavax and the ongoing
development of its vaccine and adjuvant products are forward-looking
statements. Novavax cautions that these forward looking statements are
subject to numerous risks and uncertainties, which could cause actual results
to differ materially from those expressed or implied by such statements.
These risks and uncertainties include those identified under the heading "
Risk Factors
" in the Novavax Annual Report on Form 10-K for the year ended December 31,
2013, and filed with the Securities and Exchange Commission (SEC). Investors
are cautioned not to place considerable reliance on the forward-looking
statements contained in this press release. You are encouraged to read
company filings with the SEC, available at sec.gov, for a discussion of these
and other risks and uncertainties. The forward-looking statements in this
press release speak only as of the date of this document, and the company
undertakes no obligation to update or revise any of the statements. The
company
'
s business is subject to substantial risks and uncertainties, including those
referenced above. Investors, potential investors, and others should give
careful consideration to these risks and uncertainties.

CONTACT: Barclay A. Phillips
SVP, Chief Financial Officer and Treasurer
Novavax, Inc.
240-268-2000

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novavax, Inc. via Globenewswire

HUG#1783255

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.